• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Doug Long on the Impact of Telehealth on Specialty Pharmacy

Video

The pandemic drove telehealth usage, but it has challenges that might prevent doctors from prescribing new therapies, said Doug Long, MBA, vice president, industry relations, IQVIA.

The pandemic drove telehealth usage, but it has challenges that might prevent doctors from prescribing new therapies, said Doug Long, MBA, vice president, industry relations, IQVIA.

Transcript

What impact did the pandemic and the shift to telehealth have on the growth of the specialty pharmacy market?

Well, first of all, COVID[-19] created telehealth. It barely existed prior to [COVID-19], and in the early stages of COVID-19, telehealth reached 15% of the medical claims. Now, it's down to 4%. So, it's seeking its level right now.

The handicap on telehealth is they don't have access to the labs and the vitals and things that make doctors comfortable with prescribing new therapies. So, that's the challenge that telehealth is going to have.

Saying that, it really depends on what specialty you're talking about—how relevant telehealth is—because particularly in mental health now, it's a huge thing in mental health.

Related Videos
Surbhi Sidana, MD, MBBS
Mabel Mardones, MD.
Mei Wei, MD.
Screenshot of Susan Wescott, RPh, MBA
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Screenshot of an interview with Stuart Staggs
Screenshot of an interview with Adam Colborn, JD
Screenshot of Stephanie Hsia, PharmD
Screenshot of an interview with James Chambers, PhD
Screenshot of an interview with Megan Ehret, PharmD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.